menu
    • menu

    Company profile for Contineum Therapeutics

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Contineum Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with significant unmet medical needs. Our focus is on targeting biological pathways associated with specific clinical disabilities, aiming to modulate them in ways that can positively impact the course of disease. The c...
    Contineum Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with significant unmet medical needs. Our focus is on targeting biological pathways associated with specific clinical disabilities, aiming to modulate them in ways that can positively impact the course of disease. The company boasts a robust pipeline of internally developed programs aimed at addressing various NI&I disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Contineum TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Diego, CA 92121
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.contineum-tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/contineumtherapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Contineum Therapeutics Releases Positive Results From PIPE-791
    Contineum Therapeutics Releases Positive Results From PIPE-791

    30 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7257144

    FIRSTWORD PHARMA
    30 Apr 2026
    Share Share
    Contineum Therapeutics Reports Inducement Grant Under Nasdaq
    Contineum Therapeutics Reports Inducement Grant Under Nasdaq

    13 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260313649739/en/Contineum-Therapeutics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635c4

    BUSSINESSWIRE
    13 Mar 2026
    Share Share
    Contineum Reports Fourth-Quarter 2025 Financial Results
    Contineum Reports Fourth-Quarter 2025 Financial Results

    05 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260305029664/en/Contineum-Therapeutics-Reports-Fourth-Quarter-2025-Financial-Results-Affirms-Key-Clinical-Development-Milestones

    BUSSINESSWIRE
    05 Mar 2026
    Share Share
    Continuum Therapeutics to Present at 2026 Leerink Conference
    Continuum Therapeutics to Present at 2026 Leerink Conference

    03 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260303064253/en/Contineum-Therapeutics-to-Present-at-the-2026-Leerink-Partners-Global-Healthcare-Conference

    BUSINESSWIRE
    03 Mar 2026
    Share Share
    Contineum Therapeutics Discloses Inducement Grant Per Nasdaq LR
    Contineum Therapeutics Discloses Inducement Grant Per Nasdaq LR

    18 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260218230467/en/Contineum-Therapeutics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    18 Feb 2026
    Share Share
    Continuum Therapeutics Inducement Under Nasdaq Rule 5635(c)(4)
    Continuum Therapeutics Inducement Under Nasdaq Rule 5635(c)(4)

    28 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260128919609/en/Contineum-Therapeutics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    28 Jan 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search